Global Alzheimer’s Drugs Market Set for Rapid Growth, to Reach USD 5.09 billion by 2022

13-Dec-2017 | Zion Market Research

Zion Market Research has published a new report titled “Alzheimer’s Drugs Market by Drug Class (Cholinergic, Memantine, and Combined Drug), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and by Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2014 - 2022”. According to the report, global Alzheimer’s drugs market was valued at approximately USD 3.42 billion in 2016 and is expected to generate revenue of around USD 5.09 billion by end of 2022, growing at a CAGR of around 8% between 2017 and 2022. 

Alzheimer’s is a neurodegenerative, progressive disease of the brain, which leads to loss of memory and cognitive functions. It also involves parts of the brain which control thought, memory, and language and over time can seriously affect a person’s ability to carry out daily activities. Alzheimer's is the most common form of dementia, and it accounts for 60-80% of dementia cases. As Alzheimer's is a progressive disease, in which symptoms of the disease gradually worsen over a number of years. This disease has no current cure, but treatments for symptoms are available and research continues.

Browse the full "Alzheimer’s Drugs Market by Drug Class (Cholinergic, Memantine, and Combined Drug), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and by Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2014 - 2022" report at https://www.zionmarketresearch.com/report/alzheimers-drugs-market

Global Alzheimer’s drugs are primarily driven by worldwide growing prevalence of Alzheimer’s disease, increasing awareness about the treatment of Alzheimer’s disease. Other major driving factors of Alzheimer’s drugs market are, several neurodegenerative diseases have become increasingly prevalent in the developing countries such as the U.S. in the past few years. This is leading to a steady support from the government to develop a drug for treatment.  However, high prices of the advanced drugs can create restraints to the Alzheimer’s drugs market in the developing countries like the Asia Pacific. Additionally, awareness about Alzheimer’s disease remains restricted, which has resulted in unstable healthcare systems and uncooperative research infrastructure in developing countries may limit the growth of the market. 

Global-Alzheimer%E2%80%99s-Drugs-Market.png

The Alzheimer’s Drugs are segmented on the basis of drug class including cholinergic, memantine and combined drug. On the basis of the distribution channel, Alzheimer’s drugs are segmented as hospital pharmacy, retail pharmacy, and online sales. Of these, memantine is likely to remain the leading contributor to the global Alzheimer's drugs market in the near future; it is primarily due to the lack of effective drug classes in several developing regions. Combined drug treatment is also likely to remain a major contributor to the global Alzheimer's drugs market in the coming years due to the growing recognition of its efficacy and rising availability in developed countries.

North America, Europe, Asia-Pacific, Latin America and Middle East & Africa are key regional segments of global Alzheimer’s drugs. North America is projected to dominate the global Alzheimer’s drugs market. Owing to rising prevalence of disease across this region and presence of global players which has made distribution easier in the region are the key factors responsible for the large share of this regional segment. However, Europe also has an immense potential for expansion, due to growing geriatric population. Asia Pacific is also expected to expand at a considerable high rate, displaying a promising CAGR during the forecast period. 

Some of the key players in Alzheimer’s Drugs are Ono Pharmaceutical, Johnson & Johnson, Daiichi Sankyo Company Limited, H Lundbeck A/S,  Eisai Co Ltd., and among others.

This report segments the global Alzheimer’s Drugs is as follows:

Global Alzheimer’s Drugs: by Drug Class

  • Cholinergic
  • Memantine
  • Combined Drug 

Global Alzheimer’s Drugs: by Distribution Channel

  • Hospital Pharmacy 
  • Retail Pharmacy
  • Online Sales

Global Alzheimer’s Drugs: By Region

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

About Us

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States.

Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

 

Download Brochure
Latest Published Reports

View All Published Reports